 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
The Medicines Company (MDCO) is a pharmaceutical company. The firm provides various medicines to hospitals for advancing the treatment of critical care patients worldwide.
The company markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty and for use in patients undergoing percutaneous coronary intervention; and Cleviprex, an intravenous small molecule calcium channel blocker for the reduction of blood pressure, as well as to treat neurocritical care and cardiac surgery patients.
Its products under development include Cangrelor that is in Phase III clinical trial acts as an intravenous small molecule antiplatelet agent to prevent platelet activation and aggregation; and Oritavancin, which is in Phase III clinical trial acts as an investigational intravenous antibiotic for the treatment of serious gram-positive bacterial infections, including acute bacterial skin and skin structure infections. The companys products under development also comprise MDCO-157, a pre-registration stage product for platelet inhibition in patients suffering from acute coronary syndrome (ACS), and patients experiencing myocardial infarction, stroke, or peripheral arterial disease; MDCO-2010, a small molecule serine protease inhibitor that is in Phase II clinical trial used for the reduction of blood loss during surgery; and MDCO-216, which is in Phase I clinical trial used for the reversal of atherosclerotic plaque development and the reduction of the risk of coronary events in patients with ACS.
Its products also consist of Argatroban, a direct thrombin inhibitor used as anticoagulant for prophylaxis or for the treatment of thrombosis; and acute care generic products.
Shares have formed a bullish "flag" after the firm announced positive results on its phase III candidate, cangrelor. This is the second positive development on the pipeline front from the company. A few weeks back, MDCO had announced positive results on its phase III antibiotic candidate, oritavancin.
Higher prices are expected for this stock.
52-Week Trading Range: $18.60 - $29.95
Entry Point: $29.75
Stop Loss: $28.30
Target Price: $32.79
We are closing MDCO with a 3.7% gain at $30.78. It is less than the 10% gain expected but a profit is a profit!
